Immunity and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China
Condition: Hand, Foot and Mouth Disease Interventions: Biological: The first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor; Biological: The second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor; Biological: The third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor ; Biological: The first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor; Biological: The second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor; Biological: The third batch of inactivated EV-A71 vaccine (v...
Source: ClinicalTrials.gov - March 28, 2019 Category: Research Source Type: clinical trials
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
Conditions: Enterovirus; Rhinovirus Interventions: Drug: Nitazoxanide; Drug: Placebo Sponsor: Romark Laboratories L.C. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 30, 2018 Category: Research Source Type: clinical trials
